Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

STRO vs OKYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STRO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–3 Matrix Metrics)

STRO Overall Winner 6-Pillar Tally: STRO 3 – 1 OKYO (2 Tie) Matrix Metrics: STRO 5 – 3 OKYO

As of Nov 20, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). STRO carries a Unified Composite Score of 44.1/100 (HOLD) at $8.60 (10.0x Forward P/E, -254.7% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: STRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STRO vs OKYO
STRO NASDAQ Head-to-Head Winner
Sutro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
$8.60
-1.38% 1D
Market Cap $144.8M
TTM Revenue $45M
Forward P/E 10.0x
Beta / 30D Vol 1.46β · 76% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.6%), weak momentum, RSI 35
RSI-14: 34.5 · SMA20: $9.36 · SMA50: $12.22
OKYO NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38

6-Pillar Scorecard Institutional Category Breakdown (STRO 3 – 1 OKYO)

Columns: Metric · STRO · OKYO
1. Valuation Multiples STRO
Forward P/E 10.0x N/M
Trailing P/E 10.0x N/M
PEG Ratio N/M N/M
EV / Revenue 3.2x N/M
2. Growth & Scale STRO
Revenue Growth (YoY) -6.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $45M N/A
Market Cap $144.8M $62.7M
3. Profitability & Quality OKYO
Gross Margin N/A N/A
Operating Margin -254.7% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1810.0% -263.8%
4. Balance Sheet & Cash Flow STRO
Cash Generation (TTM) -$109M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -1810.0% ROE $0.23 Book/Sh · -263.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 122.4% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STRO (5) vs OKYO (3)
Institutional Metric STRO OKYO Criterion Row Edge
Market Capitalization
Scale
$144.8M $62.7M Larger Scale STRO
Trailing P/E Ratio
Valuation
10.0x N/M Lower Multiple STRO
Forward P/E Ratio
Valuation
10.0x N/M Lower Multiple STRO
Revenue Growth (YoY)
Growth
-6.1% +0.0% Higher Growth OKYO
Operating Margin (TTM)
Profitability
-254.7% 0.0% Higher Margin OKYO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1810.0% -263.8% Higher ROE OKYO
52-Week Range Position
Momentum
18% ($1–$44) 3% ($1–$3) Stronger Trend STRO
Beta / 30D Volatility
Risk Regime
1.46β · 76% Vol 1.05β · 76% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite STRO
Trailing 12M Revenue (USD)
Operating Scale
$45M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$109M EBITDA (-1810.0% ROE) N/A ($0.23 Book/Sh · -263.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STRO +10.79 pp
STRO: -16.42% · OKYO: -27.21%
3M Horizon OKYO +29.36 pp
STRO: -58.03% · OKYO: -28.67%
6M Horizon OKYO +32.01 pp
STRO: -66.37% · OKYO: -34.36%
1Y Horizon STRO +892.08 pp
STRO: +845.05% · OKYO: -47.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STRO vs OKYO. Trailing 12-month operating profitability (STRO -254.7% vs OKYO 0.0%) and valuation multiples (STRO 10.0x vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

STRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$45M
Gross MarginN/A
Op. Margin-254.7%
ROE / Fwd P/E-1810.0% · 10.0x
OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 122.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $144.8M market capitalization and -254.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STRO vs OKYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). STRO carries a Unified Composite Score of 44.1/100 (HOLD) at $8.60 (10.0x Forward P/E, -254.7% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: STRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STRO leads the Growth & Scale pillar: STRO posts -6.1% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (N/A gross margin, -254.7% operating margin), compared with OKYO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, STRO generates $45M in USD-normalized revenue versus N/A for OKYO. In operating R&D and SG&A reinvestment, STRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKYO.

STRO screens cheaper on headline valuation multiples. STRO trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported EBITDA margin), whereas OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STRO (-1810.0% ROE) versus OKYO (-263.8% ROE) capital efficiency.

In options market volatility and institutional positioning, STRO carries 122.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.46β · 76% Vol realized risk). By comparison, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.